Validation of in silico biomarkers for drug screening through ordinal logistic regression

6Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Since the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiation, many studies have suggested various in silico features based on ionic charges, action potentials (AP), or intracellular calcium (Ca) to assess proarrhythmic risk. These in silico features are computed through electrophysiological simulations using in vitro experimental datasets as input, therefore changing with the quality of in vitro experimental data; however, research to validate the robustness of in silico features for proarrhythmic risk assessment of drugs depending on in vitro datasets has not been conducted. This study aims to verify the availability of in silico features commonly used in assessing the cardiac toxicity of drugs through an ordinal logistic regression model and three in vitro datasets measured under different experimental environments and with different purposes. We performed in silico drug simulations using the Tomek-Ohara Rudy (ToR-ORD) ventricular myocyte model and computed 12 in silico features comprising six AP features, four Ca features, and two ion charge features, which reflected the effect and characteristics of each in vitro data for CiPA 28 drugs. We then compared the classific performances of ordinal logistic regressions according to these 12 in silico features and used in vitro datasets to validate which in silico feature is the best for assessing the proarrhythmic risk of drugs at high, intermediate, and low levels. All 12 in silico features helped determine high-risky torsadogenic drugs, regardless of the in vitro datasets used in the in silico simulation as input. In the three types of in silico features, AP features were the most reliable for determining the three Torsade de Pointes (TdP) risk standards. Among AP features, AP duration at 50% repolarization (APD50) was the best when individually using in silico features per in vitro dataset. In contrast, the AP repolarization velocity (dVm/dtMax_repol) was the best when merging all in silico features computed through three in vitro datasets.

References Powered by Scopus

Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation

967Citations
N/AReaders
Get full text

Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium

455Citations
N/AReaders
Get full text

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress

317Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Explainable artificial intelligence (XAI) to find optimal in-silico biomarkers for cardiac drug toxicity evaluation

2Citations
N/AReaders
Get full text

A stacking ensemble machine learning model for evaluating cardiac toxicity of drugs based on in silico biomarkers

2Citations
N/AReaders
Get full text

qInward variability-based in-silico proarrhythmic risk assessment of drugs using deep learning model

2Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jeong, D. U., Danadibrata, R. Z., Marcellinus, A., & Lim, K. M. (2022). Validation of in silico biomarkers for drug screening through ordinal logistic regression. Frontiers in Physiology, 13. https://doi.org/10.3389/fphys.2022.1009647

Readers' Seniority

Tooltip

Lecturer / Post doc 2

50%

PhD / Post grad / Masters / Doc 2

50%

Readers' Discipline

Tooltip

Engineering 3

60%

Agricultural and Biological Sciences 1

20%

Chemistry 1

20%

Save time finding and organizing research with Mendeley

Sign up for free